Takeaway
An increased Framingham risk score at baseline was associated with a greater risk of relapses, disability and escalation of disease-modifying treatment (DMT) in people with multiple sclerosis (MS).
Why this matters
The impact of multiple cardiovascular risk factors using the Framingham risk score in people with MS has not been assessed.
The results of this novel study may help with the long-term management of MS.